Exome sequencing can be a valuable tool to diagnose unexplained neurogenetic disorder. Athena Diagnostics’ Neurome™ Neurological Exome test (powered by Personalis®) is the first exome sequencing focused on neurological disease, with superior coverage and interpretation to help clinicians end the diagnostic odyssey.
The Neurome™ Neurological Exome test is powered by Personalis®’s ACE (Accuracy and Content Enhanced) exome technology and guided by cutting-edge phenotype-driven analysis. It can pinpoint the genetic cause of many neurological disorders including:
Coverage/Technical Sensitivity: Personalis®’s has finished over 6,000 genes (>99% of bases covered at 20x or above), and includes medically-interpretable regions outside the exome in introns, UTRs, and promoters.
In an internal study, Personalis’ ACE Exome technology enabled it to find causative mutations in ~56% of patients, compared to ~25% with other technologies.
The American College of Medical Genetics endorses exome sequencing when (ACMG):
Athena Diagnostics Client Services - (800) 394-4493 Option 2
Athena Diagnostics Genetic Counselors - Genetics@AthenaDiagnostics.com
Athena Diagnostics knows that the diagnostic odyssey can be challenging. The Neurome test reads the entire exome, which is the part of the human genome that encodes for genes, and reports variants on all genes associated with neurological disease.
This test takes 10-15 weeks to complete, and is not available in the state of California.
Athena Diagnostics is a leader in diagnostic testing for neurological diseases and offers innovative tests for Alzheimer's disease, muscular dystrophy and other neuromuscular and developmental disorders.
View Full Catalog
Accreditations and Licensing
Athena Diagnostics, Inc.
200 Forest Street, 2nd Floor
Marlborough, MA 01752
Copyright © 2017 Athena Diagnostics, Inc. All trademarks and service marks identified by ®, ™ or ℠ symbols or appearing in type form different from that of the surrounding text are marks owned by or licensed to Athena Diagnostics, Inc., its subsidiaries or affiliates, unless otherwise identified as being owned by another entity. See Full Notice